This was a randomised, double-blind, placebo-controlled phase 2 trial at 24 centres in the USA. It assigned 179 adults with obesity, or with overweight plus at least one weight-related condition, and without type 2 diabetes, to once-weekly subcutaneous mazdutide at 3-6 mg, 10 mg or 16 mg, or to placebo, for 48 weeks. Mean age was 47.7 years (SD 12.3) and 118 participants (66%) were women. The primary endpoint was percentage change in bodyweight at 32 weeks.
At 32 weeks, least-squares mean weight change was -7.3% (SE 0.9) on 3-6 mg, -15.6% (0.7) on 10 mg and -18.1% (1.0) on 16 mg, against -0.9% (0.8) on placebo. Treatment differences versus placebo ran from -6.5% to -17.2%, all p<0.0001, and weight continued to fall out to 48 weeks. Mazdutide adds glucagon receptor agonism to GLP-1, which is a different lever from the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) combination used by tirzepatide, and the ceiling reached here looks broadly comparable. The cost sits in tolerability: 20% of the 16 mg group stopped treatment for adverse events, mostly gastrointestinal.
This is research-stage and belongs in the watch column, not the prescribing one. Phase 2, 179 people, no active comparator, and a population selected to exclude type 2 diabetes - none of that tells you how mazdutide performs against semaglutide or tirzepatide, or what it does to HbA1c. Its relevance to Asian practice is that mazdutide has been developed principally outside the USA, and this trial extends the tested dose range up to 16 mg in a US population; a dose range studied across different populations is what eventually makes a drug usable in a clinic like yours.
- Do not offer mazdutide to patients - it is investigational and this is phase 2 evidence.
- When a patient asks about a new stronger weight drug, quote the discontinuation figure alongside the weight figure: one in five stopped at 16 mg.
- Note the trial excluded type 2 diabetes; weight loss percentages in people without diabetes are usually larger than in people with it.
- Compare like with like - this is 32-week data, while most headline figures for other agents come from 68 to 72 weeks.
- Wait for phase 3 results with an active comparator before forming a view on where it sits against existing drugs.
The statistics, in plain English
The weight figures are reported with SE, the standard error, not SD, the standard deviation. SE describes how precisely the group average was measured; it is not how much individuals varied, and it is always the smaller and more flattering of the two. So -18.1% (SE 1.0) means the average is well pinned down, and tells you nothing about how many participants lost 5% or 30%. The p<0.0001 against placebo is easy to achieve when the placebo group lost only 0.9%, and says nothing about whether mazdutide beats an existing drug. With 179 participants over 48 weeks, uncommon harms simply cannot appear. And because there was no active comparator, every comparison you will read against semaglutide or tirzepatide is being made across separate trials with different populations, which is the least reliable form of comparison there is.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free